冠心通脉胶囊对冠心病患者动脉粥样硬化相关细胞因子的影响

目的:观察冠心通脉胶囊对冠心病心绞痛患者白细胞介素6(IL-6)、肿瘤坏死因子α(TNF-α)、内皮细胞微颗粒(EMPs)和血管性血友病因子(vWF)含量的影响,探讨其可能的作用机制.方法:将60例冠心病心绞痛患者随机分为治疗组(冠心通3粒/次,3次/d)和对照组(通心络胶囊,3粒/次,3次/d),4周为1个疗程,比较2组临床疗效以及服药前后IL-6,TNF-α,EMPs,vWF含量变化.结果:心电图观察显示,治疗组总有效率85.7％,对照组总有效率90.0％,2组间无显著性差异；临床疗效治疗组总有效率92.9％,对照组总有效率93.3％,2组间无显著性差异；治疗组和对照组的IL-6,TNF-α,EMPs,vWF治疗后均下降明显,前后比较有显著性差异(P＜0.01),2组间比较无显著性差异.结论:冠心通脉胶囊能明显降低冠心病心绞痛患者IL-6,TNF-α,EMPs,vWF的含量,在治疗冠心病心绞痛疗效上与通心络胶囊相当,其作用机制可能与抗炎症反应有关.

Effects of Guanxin Tongmai Capsule on Cytokinesrelated to Atherosclerosis in Patients with Coronary Heart Disease

Objective:To observe the levels of Guanxin Tongmai capsule on interleukin 6(IL-6),tumor kecrosis fator-α(TNF-α),endothelial cells micro particles(EMPs) and von willebrand factor(vWF) in patients with coronary heart disease and the action mechanism of Guanxin Tongmai capsule.Method:Sixty patients were divided randomly into treatment group(Guanxin Tongmai capsule 3# Tid) and control group(Tongxinluo capsule 3# Tid).After 4 weeks treatment,the results of IL-6,TNF-α,EMPs and vWF and the clinical effects were compared between the two groups.Result:There were no significant difference between the treatment group(85.7%)and the control group(90.0%) on ECG,no significant difference between the treatment group(92.9%)and the control group(93.3%) on clinical effect.The content of IL-6,TNF-α,EMPs and vWF in the two groups were both significantly decreased after treatment,no statistically significant difference between the two groups.Conclusion:Guanxin Tongmai capsule could decrease the content of IL-6,TNF-α,EMPs and vWF in the patients with coronary heart disease.Guanxin Tongmai capsule can play a considerable role compared with Tongxinluo capsule,the action mechanism may be anti-inflammatory.